Samples of 27 drugs manufactured in Himachal found substandard

As many as 27 drug samples, manufactured at pharmaceutical units of Himachal Pradesh at Baddi, Nalagarh, Paonta Sahib, Kala Amb, Solan and Kangra, have been declared sub substandard by the Central Drugs Standard Control Organisation (CDSCO).

These figure among the list of 111 drug samples declared not of standard quality and the Central Drugs Standard Control Organization (CDSCO) has issued a drug alert regarding this.

The list released on December 27, is part of the continuous regulatory surveillance where drugs samples are picked from sales/distribution points and analysed.

CDSCO releases list of the medicines that do not meet the standards and in month of November a total of 111 drug samples failed. Out of these 27 drugs were manufactured in Himachal. Most of the these drugs are used in the treatment of heart diseases, high blood pressure, pain, antibiotics and other diseases, including allergies.

State drugs controller Manish Kapoor said they were closely regulating the manufacturing through regular inspections where compliance was ensured in firms lacking regulatory parameters.

He said about 142 companies have been ordered to stop manufacturing following certain flaws that were noticed during inspection. Kapoor said that action will be taken as per rules against the companies whose drug samples have failed. Notices have been issued to these drug companies.

Related Posts

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

The report emphasizes that absolute R&D spending remains modest and identifies expanding investment in advanced biologics and AI-driven drug discovery as the “largest opportunity” for bridging the innovation divide. Recent…

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Early-stage activity drove the month, accounting for 73.6 per cent of total investments, while seed-stage rounds contributed the remaining 26.4 per cent. India’s pharma and healthcare funding for November 2025…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Novo Nordisk gears up for December Ozempic launch

Novo Nordisk gears up for December Ozempic launch

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit